Lyka Labs Limited (LYKALABS) fundamentals
Lyka Labs Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as LYKALABS (ISIN INE933A01014). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Lyka Labs Limited does
Lyka Labs Limited is an India-based pharmaceutical company engaged in the development, manufacture and marketing of quality finished dosages. The Company manufactures pharmaceutical products such as Dry Powder, Liquid, Lyophilized Injections and External Preparations for several International Markets and the Domestic Market. The Company’s R&D is engaged in the development of new formulations and has developed several products in the categories, such as Injectables: Lyophilized Injection, Liquid Injections & Dry Powder Injections, and Topical Preparation: Ointment /Creams and Lotions. It offers formulations, such as emollient, anti-aging, cleansing lotion, hair care products, anti-dandruff shampoo, sunscreen, anti-acne, antioxidant tablets, antioxidants combination, proton pump inhibitor, antifungal, anti-malarial, antibacterial, corticosteroid hormones and cephalosporins. The Company's subsidiaries include Lyka BDR International Limited and Lyka Exports Limited.
Valuation and market data
| Last close | ₹82.90 |
|---|---|
| Market capitalisation | ₹308 crore |
| Enterprise value | ₹336 crore |
| P/E (TTM) | 0.00 |
| Price to book | 3.39 |
| Price to sales (TTM) | 1.28 |
| Book value per share | ₹24.45 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Jan 12 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹125 crore | ₹-33 crore | ₹-32 crore | -9.05 |
| Mar 2025 | ₹137 crore | ₹11 crore | ₹8 crore | 2.19 |
| Mar 2024 | ₹108 crore | ₹-1 crore | ₹-2 crore | -0.72 |
| Mar 2023 | ₹84 crore | ₹-13 crore | ₹-13 crore | -4.65 |
| Mar 2022 | ₹167 crore | ₹60 crore | ₹40 crore | 13.90 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 58.5% |
|---|---|
| Foreign institutions (FII) | 0.2% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.7% |
| Retail and others | 40.7% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.